Omeprazole (GastroGard / UlcerGard)

Omeprazole is a proton pump inhibitor (PPI) that represents the gold standard for treating and preventing gastric ulcers in horses. Available under the brand names GastroGard (treatment formulation) and UlcerGard (prevention formulation), omeprazole is one of the few medications FDA-approved specifically for use in horses, reflecting its established safety and efficacy in equine patients. The medication works by providing profound and sustained suppression of gastric acid production, creating an environment that allows ulcerated gastric tissue to heal. Equine gastric ulcer syndrome (EGUS) affects a remarkably high percentage of horses, particularly those in performance disciplines, making omeprazole one of the most commonly prescribed medications in equine medicine.

The mechanism of action of omeprazole involves irreversible inhibition of the hydrogen-potassium ATPase enzyme system, commonly known as the proton pump, located in the parietal cells of the stomach lining. This enzyme is responsible for the final step of gastric acid secretion, pumping hydrogen ions into the stomach lumen in exchange for potassium ions. By covalently binding to and inactivating this pump, omeprazole effectively shuts down acid production regardless of what stimulus is triggering secretion. Because the inhibition is irreversible, acid secretion only resumes when new proton pump proteins are synthesized, resulting in sustained acid suppression that lasts significantly longer than the medication's plasma half-life.

Omeprazole is available in formulations specifically designed for horses, with GastroGard and UlcerGard being the FDA-approved products. Both are formulated as oral paste in calibrated syringes, with GastroGard containing a higher concentration for treatment doses and UlcerGard designed for prevention doses. Generic omeprazole formulations and compounded preparations are also available, though bioavailability may vary compared to the approved products. The medication is administered once daily, making it convenient for horse owners compared to medications requiring multiple daily doses. The oral paste is generally well-accepted by horses, though some individuals may require creative administration techniques.

The safety profile of omeprazole in horses is well-established through extensive clinical use and research. The medication is generally well-tolerated, with few adverse effects reported at recommended doses. Omeprazole has been studied more thoroughly than most other equine gastroprotective medications, providing veterinarians and horse owners with confidence in its use. However, the medication is not without considerations, including cost, potential effects of long-term acid suppression, and the importance of accurate diagnosis before initiating treatment. Veterinary guidance ensures appropriate use of omeprazole and helps differentiate gastric ulcers from other conditions that may present with similar signs.

The primary indication for omeprazole in horses is the treatment of equine gastric ulcer syndrome (EGUS), a condition that affects a substantial proportion of the equine population. Studies have consistently demonstrated that 50 to 90 percent of horses, depending on use and management, have some degree of gastric ulceration, with the highest prevalence in performance horses including racehorses, show horses, and endurance horses. EGUS encompasses ulceration of both the squamous (non-glandular) and glandular portions of the equine stomach, though lesions in the squamous region are more common and more responsive to omeprazole therapy. The medication's ability to raise gastric pH above 4 for extended periods creates optimal conditions for mucosal healing.

Omeprazole is equally important for the prevention of gastric ulcers in horses at risk due to management factors, training intensity, or stressful circumstances. Horses in intensive training programs, those with limited turnout, animals receiving infrequent meals, and those undergoing transportation or competition are at elevated risk for ulcer development. UlcerGard is FDA-approved for ulcer prevention at a lower dose than the treatment dose, providing a convenient option for maintaining gastric health in at-risk horses. Prevention is particularly valuable because subclinical ulceration can affect performance, appetite, and behavior without overt clinical signs.

The treatment of squamous gastric ulceration represents the most evidence-based application of omeprazole, with healing rates of 70 to 90 percent or higher achieved with appropriate dosing and duration. Treatment protocols typically involve administering the full treatment dose (4 mg/kg) for 28 days, followed by gastroscopic examination to confirm healing. Some horses require extended treatment courses, and recurrence is common if predisposing factors are not addressed. The medication is highly effective for squamous ulcers, which occur in the upper portion of the stomach and are exposed to acid during periods of gastric emptying.

Glandular gastric ulceration, affecting the lower portion of the stomach, represents a more challenging condition to treat. While omeprazole improves glandular ulcer healing compared to no treatment, response rates are lower than for squamous disease, and combination therapy with sucralfate or other agents may be recommended. The pathophysiology of glandular ulceration may involve factors beyond acid exposure, including bacterial infection, impaired mucosal defense, and reduced blood flow. Horses with glandular ulceration often require extended treatment courses and may benefit from additional therapeutic interventions.

Additional clinical applications of omeprazole include treatment of horses with suspected ulcer-related clinical signs such as poor appetite, behavioral changes, girthiness, poor coat condition, mild recurrent colic, and suboptimal performance. The medication may be used diagnostically in some cases, where improvement during a treatment trial supports (though does not definitively confirm) the diagnosis of gastric ulceration. Omeprazole is also used in foals with gastric ulceration, which is common in neonates experiencing stress or illness.

Dosing of omeprazole in horses is well-established through FDA-approval studies and extensive clinical experience. The medication is administered orally once daily, with the specific dose depending on whether the goal is treatment of existing ulcers or prevention of ulcer development. Accurate weight determination is important for calculating the correct dose, as both underdosing and significant overdosing should be avoided. The convenience of once-daily dosing, combined with the calibrated paste syringe delivery system, makes omeprazole relatively straightforward to administer compared to medications requiring multiple daily doses.

The treatment dose of omeprazole for healing established gastric ulcers is 4 milligrams per kilogram of body weight, administered once daily. For a 500-kilogram (1,100-pound) horse, this translates to 2,000 milligrams (2 grams) daily. GastroGard is formulated to deliver this treatment dose, with each syringe containing enough paste for several days of treatment depending on horse size. The prevention dose, used to reduce ulcer development in at-risk horses, is 1 milligram per kilogram once daily—one-quarter of the treatment dose. UlcerGard is designed for this prevention dosing regimen.

The standard treatment duration for gastric ulcer healing is 28 days at the full treatment dose. This protocol is based on clinical trials demonstrating optimal healing rates with this duration. Some horses with severe ulceration or glandular disease may require extended treatment beyond 28 days. Following the treatment course, gastroscopic examination is recommended to confirm ulcer resolution before discontinuing therapy or transitioning to a prevention dose. Horses at ongoing risk may continue on the lower prevention dose after healing is achieved.

Administration of omeprazole paste is accomplished by inserting the syringe into the side of the horse's mouth, advancing it to the back of the tongue, and depositing the paste. The horse should not have food in its mouth at the time of administration, as food interferes with absorption. Ideally, omeprazole is given on an empty stomach, with feeding delayed for at least 30 to 60 minutes after administration. This timing maximizes the medication's bioavailability and effectiveness. Some horses readily accept the paste, while others may require gentle restraint or alternative administration techniques.

If a dose of omeprazole is missed, it should be given as soon as remembered, and the regular schedule resumed the following day. Missing occasional doses during a treatment course is unlikely to significantly impact overall healing, though consistent daily administration produces optimal results. Owners should not double doses to compensate for missed administrations. If treatment interruptions are anticipated or multiple doses are missed, veterinary consultation helps determine the best approach for continuing therapy.

Completing the full prescribed treatment course is essential for optimal ulcer healing. Premature discontinuation, even when clinical signs improve, may result in incomplete healing and rapid recurrence of ulceration. Following treatment, a gradual transition to prevention dosing or careful management changes may help reduce recurrence risk. Abrupt discontinuation of acid suppression can result in rebound acid hypersecretion, potentially exacerbating ulceration.

Omeprazole is generally very well-tolerated in horses, with adverse effects occurring infrequently at recommended doses. The medication's established safety profile, supported by FDA-approval studies and extensive clinical use, provides confidence in its use for gastric ulcer management. Most horses complete treatment courses without experiencing any notable side effects. However, awareness of potential adverse effects allows horse owners to monitor appropriately and report any concerns to their veterinarian.

Common side effects of omeprazole, when they occur, are typically mild. Soft stools or mild changes in fecal consistency have been reported in some horses. Decreased appetite or changes in eating behavior occur occasionally, which is somewhat paradoxical given that the medication often improves appetite in horses with painful ulcers. Behavioral changes, including increased or decreased activity, have been noted anecdotally. Most of these effects are transient and do not require discontinuation of treatment.

Moderate side effects associated with omeprazole use include more pronounced gastrointestinal effects and potential impacts on nutrient absorption. Prolonged acid suppression may theoretically affect absorption of certain minerals, particularly calcium and magnesium, though clinical significance in horses receiving typical treatment durations is unclear. Changes in the gastric microbiome may occur with sustained pH elevation, though the implications of this are not fully understood in horses. Some practitioners have noted that horses on long-term omeprazole may experience loose stools that resolve upon discontinuation.

Serious side effects from omeprazole are rare when the medication is used at recommended doses. Concerns have been raised about potential effects on bone metabolism with very prolonged use, based on human studies, but this has not been documented as clinically significant in horses. Hypersensitivity reactions are theoretically possible with any medication but are uncommon with omeprazole. There is ongoing research into whether long-term acid suppression may have unintended consequences, but current evidence supports the safety of treatment courses of typical duration.

Rare side effects and situations warranting veterinary attention include any severe or unexpected reactions during treatment. Horses that fail to improve or worsen during omeprazole therapy should be reevaluated, as this may indicate incorrect diagnosis, particularly severe disease, or a condition unresponsive to acid suppression. Development of new clinical signs during treatment should prompt veterinary consultation. Long-term use monitoring should include periodic reassessment of the need for continued therapy and attention to overall health status.

Omeprazole has few absolute contraindications, reflecting its favorable safety profile in horses. The medication can be used in most horses requiring treatment or prevention of gastric ulcers. However, certain conditions and circumstances warrant caution or may affect the decision to use omeprazole.

Known hypersensitivity to omeprazole or other proton pump inhibitors represents a contraindication to use. While allergic reactions to PPIs are rare, horses that have previously experienced adverse reactions to omeprazole should not receive the medication again. Cross-reactivity with other proton pump inhibitors is possible. A thorough medication history helps identify horses that may have had previous reactions.

Horses with significant liver disease may require caution with omeprazole use, as the medication is metabolized by the liver. Severe hepatic impairment could affect drug metabolism and potentially increase the risk of adverse effects. Veterinary assessment of liver function may be appropriate before initiating omeprazole in horses with known or suspected hepatic disease. Dose adjustment may be considered in some cases.

The use of omeprazole in pregnant and lactating mares has not been extensively studied, though the medication has been used clinically in these populations. Pregnant mares should receive omeprazole only when the potential benefit justifies any potential risk. The medication does appear to be secreted in milk in other species, though effects on nursing foals at typical maternal doses are likely minimal. Veterinary guidance is appropriate for treatment of pregnant or nursing mares.

Foals can receive omeprazole, as gastric ulceration is common in this age group, but dosing must be appropriate for their smaller body size and potentially different pharmacokinetics. Very young foals may have different drug handling characteristics than older foals and adult horses. Specific concerns for omeprazole use in foals include the importance of maintaining adequate stomach acid for certain digestive functions in developing animals.

Omeprazole has important drug interactions related to its effects on gastric pH and hepatic drug metabolism. Understanding these interactions helps ensure optimal therapeutic outcomes when horses receive multiple medications concurrently.

The most significant category of interactions involves medications that require an acidic gastric environment for absorption or activation. Ketoconazole and itraconazole, antifungal medications that require low gastric pH for dissolution, may have substantially reduced absorption when administered with omeprazole. If these antifungals are necessary in a horse receiving omeprazole, alternative antifungal agents or special administration protocols may be needed. Certain other medications dependent on gastric acidity may similarly be affected.

Sucralfate requires an acidic environment for optimal activation and binding to ulcerated tissue. When sucralfate is used in combination with omeprazole for horses with glandular ulceration, the sucralfate should be administered before the omeprazole, typically at least 2 hours prior, to allow sucralfate activation before gastric pH is raised. This timing consideration helps preserve the efficacy of both medications.

Omeprazole is metabolized by hepatic cytochrome P450 enzymes and may affect the metabolism of other drugs processed through the same pathways. While clinically significant interactions through this mechanism are less common than with some other medications, awareness is appropriate when horses receive multiple drugs metabolized by the liver. Veterinary pharmacology consultation may be valuable for horses on complex medication regimens.

Competition considerations are particularly relevant for omeprazole given its widespread use in performance horses. The medication is regulated as a controlled medication under FEI rules, meaning it is permitted at specified detection thresholds intended to represent therapeutic use. However, detection times can vary among individual horses, and withdrawal times should be observed before competition. USEF rules similarly address omeprazole use. Racing commission rules vary and must be verified for specific jurisdictions. Current regulations should always be consulted, as rules change over time, and horses should be withdrawn from the medication appropriately before competition.

Monitoring during omeprazole therapy focuses primarily on clinical response to treatment rather than specific laboratory parameters. Horses should be observed for improvement in clinical signs associated with gastric ulceration, including appetite, attitude, behavior, and performance. Failure to improve after 2 to 4 weeks of treatment should prompt reevaluation of the diagnosis, potentially including gastroscopic examination if not previously performed. Horses with documented severe ulceration may benefit from follow-up gastroscopy to confirm healing before discontinuing treatment.

Special populations merit specific consideration when prescribing omeprazole. Foals commonly develop gastric ulceration, particularly those that are hospitalized, ill, or stressed, and may require omeprazole treatment. Dose calculations must account for smaller body size, and the safety of prolonged treatment in developing animals should be considered. Geriatric horses may have concurrent conditions affecting drug metabolism or may be more susceptible to potential effects of prolonged acid suppression. Pregnant and lactating mares can generally receive omeprazole when needed, with appropriate veterinary oversight.

Competition and performance horses represent the population most commonly receiving omeprazole, given the high prevalence of gastric ulceration in these animals. Regulatory compliance requires awareness of current rules and appropriate withdrawal times. The FEI classifies omeprazole as a controlled medication with detection thresholds, and horses must test below these thresholds at competition. Detection times vary among individuals, and conservative withdrawal periods are recommended. Racing commissions and breed organizations have varying rules that must be verified. Accurate medication records are essential for competition horses.

Administration on an empty stomach is important for optimal omeprazole absorption and efficacy. Feeding hay or grain before administration reduces bioavailability and may compromise treatment effectiveness. Delaying feeding for at least 30 to 60 minutes after administration allows adequate time for absorption. This timing requirement can be logistically challenging in some barn environments and should be incorporated into the daily routine.

Long-term use considerations are increasingly relevant as understanding of prolonged acid suppression effects develops. While omeprazole is well-tolerated during typical treatment courses, extended use may have implications for nutrient absorption, gastric microbiome composition, and potentially other factors not yet fully characterized in horses. Horses requiring ongoing acid suppression should be periodically reassessed to determine whether continued treatment is necessary and whether management modifications could reduce or eliminate the need for medication.

Proper storage of omeprazole helps maintain medication potency and effectiveness. GastroGard and UlcerGard paste syringes should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit (20-25 degrees Celsius). The medication should be protected from excessive heat, and storage in hot vehicles or non-climate-controlled barn areas should be avoided during warm weather. Freezing should also be avoided. The paste syringes should be stored with the cap in place to prevent drying of the paste.

Handling omeprazole presents minimal human safety concerns compared to many veterinary medications. The paste can be handled directly during administration without special protective equipment. Standard hygiene practices, including hand washing after handling, are appropriate. Accidental ingestion of small amounts is unlikely to cause significant effects in humans, as omeprazole is widely used in human medicine, though medical consultation is advisable for larger ingestions. The paste can be somewhat sticky and may stain fabric.

Expiration dates should be observed for omeprazole products. The paste syringes typically have shelf lives of two to three years from manufacture when stored properly. Compounded omeprazole preparations may have shorter expiration periods, typically 30 to 90 days depending on formulation, and should be used within the timeframe specified. Expired medication should not be used, as potency cannot be assured. Disposal of unused or expired omeprazole should follow appropriate guidelines, which may include community medication take-back programs. Generic and compounded omeprazole products should be evaluated for appropriate quality and storage requirements, as these may vary from the FDA-approved products.

Draft horses, including Clydesdales, Percherons, Shires, Belgians, and other heavy breeds, require dose calculations appropriate for their larger body mass when receiving omeprazole. These breeds typically weigh 1,600 to 2,200 pounds or more, substantially exceeding the weight range of light horses. Multiple syringe marks or syringes may be required to deliver the full treatment dose to large draft horses. Despite their size, draft horses are not immune to gastric ulceration, though their typically less intensive use patterns may reduce risk compared to performance horses. Management factors such as meal timing and forage access remain important regardless of breed.

Light horse breeds and warmbloods comprise the majority of horses receiving omeprazole therapy, largely due to their prevalence in performance disciplines associated with high ulcer risk. Thoroughbreds used in racing have among the highest documented ulcer prevalence, with studies showing greater than 90 percent affected in some populations. Standardbreds, Quarter Horses in intensive training, Arabians in endurance competition, and warmbloods in dressage and jumping all experience elevated ulcer rates. Standard dosing protocols apply to these breeds, with the once-daily dosing and paste syringe formulation well-suited to management of performance horses.

Ponies and miniature horses require careful dose calculation when omeprazole is prescribed. These smaller equines may weigh as little as 150 to 400 pounds for miniatures or 400 to 900 pounds for ponies, requiring proportionally smaller doses. The paste syringe calibrations are designed for horse-sized doses, so accurate measurement for small equines requires attention to the weight markings on the syringe. Miniature horses and ponies can develop gastric ulceration, though their management patterns may differ from larger performance horses. The same principles of management—frequent forage access, reduced concentrate feeding, and stress minimization—apply to small equines.

Breed-specific genetic conditions may create contexts where omeprazole use becomes relevant but do not directly affect the medication's use. Quarter Horses with HYPP, horses with PSSM, and other breeds with genetic conditions may require NSAID therapy or experience stress that predisposes to ulceration. Management of the underlying condition while maintaining gastric health requires coordinated veterinary care. There are no known breed-specific sensitivities to omeprazole itself.

Within the proton pump inhibitor class, omeprazole is the only member with FDA-approved formulations for horses and the most extensively studied in equine patients. Other PPIs used in human medicine, including esomeprazole (the S-isomer of omeprazole), pantoprazole, lansoprazole, and rabeprazole, have seen limited use in horses. Esomeprazole has been investigated in horses and may offer some advantages, but FDA-approved equine formulations are not available. When omeprazole formulations are unavailable or unaffordable, compounded preparations or, in some cases, human formulations adapted for equine use may be considered, though bioavailability and efficacy may differ.

Alternative drug classes for gastric acid management in horses include H2 receptor antagonists such as famotidine, ranitidine, and cimetidine. These medications reduce acid secretion by blocking histamine stimulation of parietal cells but provide less complete acid suppression than proton pump inhibitors. Ulcer healing rates with H2 blockers are substantially lower than with omeprazole, and more frequent dosing is required. H2 blockers may be appropriate for mild cases, prevention, or when omeprazole is unavailable, but are generally considered second-line therapy for treatment of established ulcers. Antacids such as aluminum/magnesium hydroxide provide only temporary acid neutralization and are not adequate for ulcer treatment.

Complementary therapies are often incorporated into gastric ulcer management alongside omeprazole. Sucralfate provides mucosal protection through physical coating of ulcerated tissue and may be particularly valuable for glandular ulceration. Misoprostol, a prostaglandin analog, offers protection specifically against NSAID-induced damage. Dietary management, including frequent feeding of forage, reduction of concentrate meals, and potential addition of alfalfa hay or chaff for its buffering properties, addresses underlying risk factors. Turnout and stress reduction support overall gastric health. Comprehensive ulcer management often combines appropriate medication with management modifications to reduce recurrence risk after treatment.